Indomethacin (Indometacin) sodium 是一种口服有效的COX1/2抑制剂，COX-1 和 COX-2 的IC50值分别为 18 nM 和 26 nM。Indomethacin sodium 具有抗癌和抗感染活性。Indomethacin sodium 可用于癌症、炎症和病毒感染的研究。

Indomethacin (Indometacin) sodium is a potent, orally active COX1/2 inhibitor with IC 50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin sodium has anticancer activity and anti-infective activity. Indomethacin sodium can be used for cancer, inflammation and viral infection research. [1] [2] [3].

Indomethacin (Indometacin) sodium (0-150 μM; 24 hours; 3LL-D122 cells) has anticancer activity in vitro [2]. Indomethacin (Indometacin) sodium (0-1000 μM) protects the host cells from damage caused by the virus through activates PKR, resulting in elF2α phosphorylation, and in turn shutting of translation of viral protein and inhibiting replication of the virus (IC 50 =2μM) [3]. Cell Viability Assay [2] Cell Line: 3LL-D122 cells (highly metastatic variant of mouse LLcarcinoma cells) Concentration: 0, 20, 50, 100 and 150μM Incubation Time: 24 hours Result: Inhibited cell viability at 20 mM, with 50% inhibition at 60 nM. Cell Cycle Analysis [2] Cell Line: 3LL-D122 cells (highly metastatic variant of mouse LLcarcinoma cells) Concentration: 0, 30 and 80μM Incubation Time: 24 hours Result: Decreased in the percentage of cells at the G2/M phase and increased in the percentage of cells at G1 phase.

Indomethacin (Indometacin) sodium (0.01-10 mg/kg; p.o.; for 3 hours; male Sprague-Dawley rats) induces paw oedema and hyperalgesmeasurement dose-dependently reversed carrageenan-induced hyperalgesia [1]. Indomethacin (Indometacin) sodium (10 mg/mL; p.o.; daily, for 29 days; male C57BL/6J mice) inhibits tumor growth in vivo [2]. Animal Model: Male Sprague-Dawley rats [1] Dosage: 0.01-10 mg/kg Administration: Oral administration; for 3 hours Result: Inhibited the carrageenan-induced rat paw oedema (ED 50 =2.0 mg/kg) and hyperalgesia (ED 50 =1.5 mg/kg) in a dose-dependent manner. Animal Model: Male C57BL/6J mice [2] Dosage: 10 mg/mL Administration: Oral administration; daily, for 29 days Result: Delayed the onset of tumor growth and the initial growth rate of the footpad tumors.

7681-54-1

C19H15ClNNaO4

379.77

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years